Research & Development
Policy & Regulation
Trends & Finance
Technology Development: Page 2
New task force promotes pathology for cancer research
Efforts of the task force include an award program for outstanding pathology research in cancer, knowledge hubs on pathology for medical students, and the development and adoption of new technologies in pathology. Parwani shed light on the new task force in an interview with LabPulse at the recent American Association for Cancer Research (AACR) meeting in New Orleans.
May 2, 2022
Huron Digital taps Audil Virk as president
Virk has executive leadership and operational experience in general management, strategy, product development, and technology commercialization, Huron said.
April 14, 2022
MilliporeSigma closes Exelead buy for lipid nanoparticle boost
MilliporeSigma plans to invest more than $565 million over the next 10 years to further expand Exelead's PEGylated research and development and its LNP-based drug delivery technology, which is key to mRNA vaccines and therapeutics, MilliporeSigma said.
February 22, 2022
SLAS 2022: Diagnostics tech should be based on clinical need
Traditionally, scientists and engineers create a technology, find a biological application for it, and publish it in a big academic journal. For companies, the cycle is a bit different: a company creates a technology, most likely for life sciences research, and then years (if not decades) later, someone discovers a clinical application for it.
February 9, 2022
DiaCarta, NCI to work on cancer detection technology
Under a two-year Cooperative Research and Development Agreement (CRADA), the organizations will work on investigating low-frequency mutation events in cancers and rare diseases using DiaCarta's technology, as well as develop xenonucleic acid probes for in situ cancer cell detection.
January 6, 2022
NIH announces accelerator diagnostics challenge
The contest aims to spur and reward the development of prototypes for low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies, the agency said in a release.
December 6, 2021
Point-of-care developer DCN Dx acquires IVD Vision
DCN Dx is a leading specialist developer of diagnostic tests based on lateral flow technology. The acquisition expands DCN Dx's POC diagnostics development services capabilities and product portfolio.
July 1, 2021
Expanding NIPT coverage means nominal cost increase
HPHC, which covers around 3 million people in the northeastern U.S., partnered with Illumina and the University of Colorado for the study, which evaluated the effect of a risk-sharing agreement that opened insurance coverage for these women. For the agreement, Illumina and HPHC engaged the University of Colorado as a third-party academic collaborator in 2018 to develop a study protocol, complete the analyses, and lead the publication development. The PharmacoEconomics article is the first-ever published report on a value-based agreement between a bio/medical technology company and a payer, the groups said in a press release.
March 11, 2021
Creator of Rutgers COVID-19 saliva test dies
The test earned Brooks recognition from numerous media outlets and New Jersey Gov. Phil Murphy.
January 28, 2021
Gamma announces Astrea, Avacta partnership
The licensing agreement gives Astrea access to Avacta's Affimer reagent technology for applications in bioprocessing, expanding its range of ligand discovery and development capabilities to include chemical and biological platforms for customer development programs, Gamma said.
December 22, 2020
Bluejay teams up with Toray on COVID-19 point-of-care test
Toray's Symphony interleukin 6 (IL-6) technology is a portable test for quantitation of IL-6 in whole blood for COVID-19 patients who present progressing symptoms and have a high risk of needing intubation with mechanical ventilation, according to Bluejay.
December 7, 2020
NIH invests almost $249M in 7 COVID-19 test technologies
In a July 31 press briefing, the NIH discussed seven companies that have received grants for COVID-19 tests through grants from its NIH's Rapid Acceleration of Diagnostics (RADx) initiative, which it says evaluates technology in a similar way as the reality business investment TV show Shark Tank. A range of tests are in development and the award winners include lab-based as well as point-of-care (POC) products. In a statement, the NIH said that the crop of new tests could increase the number of available tests that can be conducted each day by millions, perhaps as early as September. Funding derives from a $1.5 billion appropriation from Congress in April to support new test technologies during the COVID-19 pandemic.
July 30, 2020
Page 2 of 4